weekending:- 22-11-2019 legal publication date:- …ipo.gov.pk/system/files/191227.pdfmr. iftikhar...

Electronic Publication of Patents Journal

under The Patents (Amendments) Act, 2016

Weekending:- 22-11-2019

Legal Publication Date:- 27-12-2019

Journal Code (191227)

Patents’ journal 27-12-2019

1

NEW APPLICATIONS FOR THE PATENTS

The dates shown in the crescent brackets are the dates claimed under section 86 of the Patents

Ordinance 2000.

18/11/2019

771/2019

Monsanto Technology LLC. U.S.A.

―PLANT REGULATORY ELEMENTS AND

USES THEREOF‖

772/2019

Monsanto Technology LLC. U.S.A.

“PLANT REGULATORY ELEMENTS AND USES THEREOF”

773/2019

Monsanto Technology LLC . U.S.A.


774/2019

Monsanto Technology LLC . U.S.A.


775/2019

AIC Chile SpA, Chile.

(Priority 16/11/2018 CL)

“Method, reaction chamber and system for the treatment of liquids in continuous flow”

776/2019

Salma Bilal; Hajera Gul,; Anwar-ul-Haq Ali Shah, and Ulrike Krewer. Pakistan.

“Intrinsically conductive polymer nanocomposite with versatile abilities for energy storage”

19/11/2019

777/2019

IFTIKHAR AHMED ZAHOOR. Pakistan.

“SOLAR POWER ELECTRIC & HYBRID CAR KIT (SPECK)”

20/11/2019

778/2019

HELIO DA IGREJA. Brazil.

“THERMOCHEMICAL TREATMENT SYSTEM FOR PLASTIC AND / OR ELASTOMERIC


2

(Priority 04/12/2018 US)

WASTE”

779/2019

Prof. Dr. Shah Khusro and Mr. Iftikhar Alam. Pakistan.

“Methods And System For Real-Time Group Profile Generation and Recommendations On Smart Tv”

780/2019

DOW AGROSCIENCES LLC, U.S.A.


“N-OXIDE OF 4-AMINO-6-(HETEROCYCLIC) PICOLINATE AND 6-AMINO-2-(HETEROCYCLIC) PYRIMIDINE-4-CARBOXYLATE COMPOUND”

781/2019



“AGRICULTURALLY ACCEPTABLE SALT OF 4-AMINO-6-(HETEROCYCLIC) PICOLINATE AND 6-AMINO-2-(HETEROCYCLIC) PYRIMIDINE-4-CARBOXYLATE COMPOUND”

782/2019



“N-OXIDE OF 4-AMINO-6-(HETEROCYCLIC) PICOLINATED AND 6-AMINO-2-(HETEROCYCLIC) PYRIMIDINE-4-CARBOXYLATE COMPOUND”

783/2019

Mr. Iftikhar Alam and Prof. Dr. Shah Khusro Pakistan.

“METHOD AND SYSTEM FOR CREATING A COMPREHENSIVE E-TUTOR OF A TEXTBOOK WITH MULTIMEDIA CONTENT OF VARYING LEVELS OF DETAILS TO REDUCE TEACHING EFFORT IN ALL INSTRUCTION ENVIRONMENTS”

784/2019



“AGRICULTURALLY ACCEPTABLE SALT OF 4-AMINO-6-(HETEROCYCLIC)PICOLINATE AND 6-AMINO-2-(HETEROCYCLIC) PYRIMIDINE-4-CARBOXYLATE COMPOUND”

785/2019

Mr. Iftikhar Alam; Prof. Dr. Shah Khusro and Mr. Mumtaz khan. Pakistan.

“Methods, System and Design of a Smartphone-Based Social Assistant for Helping Blind Users in Academic Environment”

786/2019

STAUBLI FAVERGES. France.

(Priority 21/11/2018 FR)

“Cooling device for a shedding machine of a weaving machine”

787/2019

Enanta Pharmaceuticals, Inc.

“FUNCTIONALIZED HETEROCYCLES AS


3

U.S.A.


ANTIVIRAL AGENTS”

22/11/2019

788/2019

Dr. Hafiz Muhammad Tahir and Dr. Shaukat Ali Pakistan.

“Serisore”

789/2019

FMC Corporation. U.S.A.


“META-DIAMIDE COMPOUNDS FOR CONTROLLING INVERTEBRATE PESTS”

790/2019

Novartis AG. Switzerland.


“CYCLIC TETRAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS”


4

APPLICATION ACCEPTED

Notice is hereby given that the person interested in opposing the grant of Patents to any of the

applications referred to below at any time within four months from the date of this Patents’

journal may give notice at the Patent Office on the prescribed Form P-7 of the Patents Rules

18(1) of 2003.

The six figures number shown in the right hand side are those given to applications on

acceptance of the complete specification under which the specification will be printed and

subsequent proceeding taken.

The figures shown within square brackets after the title of inventions indicate their classification

index at acceptance.

Typed copies of the specification which are to open to public inspection can be supplied by the

Patent Office on payment of the prescribed charges which may be as certained on application to

the office.

683/2011


U.S.A.

―MACROCYCLIC PROLINE DERIVED HCV

SERINE PROTEASE INHIBITOR‖

A61K38/21.

143350

The present invention discloses a compound of

formula I:

which inhibits serine protease activity,

particularly the activity of hepatitis C virus

(HCV) NS3-NS4A protease. Consequently, the

compound of the present invention interferes with

the life cycle of the hepatitis C virus and is also


5

useful as an antiviral agent. The present invention

further relates to a pharmaceutical composition

comprising the aforementioned compound for

administration to a subject suffering from HCV

infection.

157/2013

Stora Enso Oyj.

Finland.

―DEEP-DRAWN PAPER TRAY, A METHOD

FOR MAKING IT‖

B32B38/12, B65D1/34, B65D1/26 &

B29C51/108.

143351

The invention concerns a deep-drawn paper tray

(4), particularly a shallow tray made of

paperboard or cardboard.The tray comprises a

bottom (4a) and upwardly expanding side walls

around the bottom, the side walls of the tray being

shaped to expand through a plurality of

circumferential steps (4b, 4c, 4d) dimensioned

low enough for obtaining wrinkle-free side walls

for the tray. The outermost step is a flat, wrinkle-

free rim flange (4d), which enables liquid and gas

proof heat-sealing of a lid to form the package.

The apparatus according to the invention may

comprise upper and lower moulding tools (10, 11)

with concentric movable frames (10b, 10c, 10d)

for forming the tray bottom and side wall steps to

paper blanks, and moulding tools (10) may be

mounted onto a rotating turret (9) carrying a paper

blank through working stations arranged along the

turret circumference, to shape the tray bottom and

the side wall steps at the consecutive stations.


6

375/2013

Novartis AG.

Switzerland.

―AN AQUEOUS COMPOSITION

COMPRISING AN ANTI-BAFFR ANTIBODY‖

C07C9/11.

143352

Anti-BAFFR antibodies are formulated as liquid

formulation comprising a high concentration of

the antibody active ingredient for delivery to a

patient without high levels of antibody

aggregation. The aqueous pharmaceutical

composition may include one or more sugars, a

buffering agent, a surfactant, and/or a free amino

acid.

476/2013

GlaxoSmithKline Intellectual

Property (No.2) Limited.

United Kingdom.

―The Non-Steroidal Compound: (R)-1 -(1 -

(méthylsulfonyl) propan-2-yl)-4-

(trifluoromethyl)-1H-indole-5-carbonitrile, and

it's use as a modulator of the androgen receptor‖

C07D401/06 & A61K31/44.

143353

The present invention relates to a compound, of

the Formula I:


7

wherein:

indicates a single or double bond;

R1 is -CF3, -C≡N, or halo;

R2 is H, C1-3 alkyl, or -CHF2;

R3 is C1-3 alkyl;

R4 is -C(CH3)(CF3)OH, -CH2SCH3, -

CH2S(O)2CH3, -C(O)CH3 or phenyl or pyridinyl,

wherein said phenyl or pyridinyl is optionally

substituted with one or two groups selected from -

C≡N and halo; and

R5 is H or methyl.

This invention relates to non-steroidal compound

that is modulator of androgen receptor, to the

method for the making and use of such

compound. This invention also provides a

pharmaceutical composition comprising a

compound to accelerate wound healing.

94/2014

Eisai R&D Management Co.,

Ltd.

Japan.

―MONOCYCLIC PYRIDINE COMPOUND AS

FGFR INHIBITOR‖

C07D401/14 & A61K 31/45.

143354

The present invention provides a novel compound

having FGFR inhibitory activity and a

pharmaceutical composition containing the same.

Specifically, the present invention provides a

compound represented by the following formula


8

(I):

wherein n represents 0 to 2; A represents an

arylene group or a heteroarylene group; G

represents a single bond, an oxygen atom or —

CH2—; E represents a nitrogen-containing non-

aromatic heterocycle; R1 represents an alkoxy

group, an alkoxy alkoxy group or the like;

R2 represents a hydrogen atom, a halogen atom, a

hydroxyl group, an alkyl group, a hydroxyl alkyl

group, a nitrogen-containing non-aromatic

heterocyclic group or the like; and R3 represents a

hydrogen atom, an alkyl group, an alkoxy group

or the like, with the proviso that when E

represents an azetidine ring and R2 or R

3 is

present on a nitrogen atom on the azetidine ring,

the R2 or R

3 does not represent a hydrogen atom.

305/2015

Novartis AG.

Switzerland.

―NOVEL PYRAZOLO PYRIMIDINE

COMPOUND AND PHARMACEUTICAL

COMPOSITION THEREOF‖

C07D487/04, A61K31/519, A61P37/00,

A61P29/00 &A61P 35/00.

143355

The present invention provides a compound of

formula (I);


9

Wherein variables R1 and R2 are as defined in the

claims of the specification.

The present invention further provides a

pharmaceutical composition comprising a

compound and one or more pharmaceutically

acceptable carriers and therapeutically effective as

a MALT1 (mucosa associated lymphoid tissue

lymphoma translocation protein 1) inhibitor.

523/2016

Eisai R&D Management Co.,

Ltd.

Japan.

―PHARMACEUTICALLY ACCEPTABLE

SALT OF MONOCYCLIC PYRIDINE

DERIVATIVE AS FGFR INHIBITOR‖

C07D401/14 & A61K31/45.

143356

The present invention provides a

pharmaceutically acceptable salt of a compound

having FGFR inhibitory activity and a

pharmaceutical composition containing the same.

Specifically, the present invention provides a


represented by the following formula (I):

wherein n represents 0 to 2; A represents an

arylene group or a heteroarylene group; G

represents a single bond, an oxygen atom or —

CH2—; E represents a nitrogen-containing non-

aromatic heterocycle; R1 represents an alkoxy

group, an alkoxy alkoxy group or the like; R2

represents a hydrogen atom, a halogen atom, a

hydroxyl group, an alkyl group, a hydroxyl alkyl

group, a nitrogen-containing non-aromatic

heterocyclic group or the like; and R3 represents a

hydrogen atom, an alkyl group, an alkoxy group

or the like, with the proviso that when E


10

represents an azetidine ring and R2 or R

3 is

present on a nitrogen atom on the azetidine ring,

the R2 or R

3 does not represent a hydrogen atom.

485/2017

Erber Aktiengesellschaft.

Austria.

―PARTICLE CONTAINING AT LEAST A

VOLATILE SUBSTANCE AND PROCESS

FOR ITS PREPARATION‖

A61K9/50 & A61K8/02.

143357

The invention is directed to a particle containing

at least a volatile substance comprising a core

comprising at least one matrix material and the at

least one volatile substance and at least one

coating layer, whereby a first coating layer is a

non-confluent layer comprising at least a carrier

material, whereby optionally the non-confluent

layer contains at least one hydrophobic substance,

and optionally the particle is surrounded by at

least one confluent layer and / or further non-

confluent layer(s) as well as to a process for

producing the same.


11

515/2017

Mr. Arish Rvaan Malik.

Pakistan.

―Cemented Heating Disc‖

H01L21/02, H05B3/74, H05B3/20, H05B 3/06 &

H05B3/10.

143358

Round shaped cemented heating disc is applied as

an industrial application to heat dies, molds &

platens. It mainly consist of 2 different parts

(Upper part & Lower Base). The Upper part is

made of Stainless sheet metal and the lower base

is a mild steel jacket that has been lathed and

milled to make a groove inside the mild steel for

supporting heating elements inside the groove to

provide even distribution of heat in the die

surface. The hole in the middle of the disc is to

adjust the cemented heating disc on the dies,

molds and platens or clamp it according to the

needs. There are two electric terminals on the

upper stainless sheet which supply current to the

elements in the groove to produce heat.

326/2018

Novartis AG.

Switzerland.

―PHARMACEUTICALLY ACCEPTABLE

SALT OF PYRAZOLO PYRIMIDINE

COMPOUND AND PHARMACEUTICAL

COMPOSITION THEREOF‖

C07D487/04 & C07D471/04.

143359


12

The present invention provides a


of formula (I);

Wherein variables R1 and R2 are as defined in the

claims of the specification. The present invention

further provides a pharmaceutical composition

comprising a pharmaceutically acceptable salt of a

compound and one or more pharmaceutically

acceptable carriers which is therapeutically

effective as a MALT1 (mucosa associated

lymphoid tissue lymphoma translocation protein

1) inhibitor.

649/2019


U.S.A.

―MACROCYCLIC PROLINE DERIVED HCV

SERINE PROTEASE INHIBITOR‖

A61K38/21.

143360

The present invention discloses a compound of

formula I:

which inhibits serine protease activity,

particularly the activity of hepatitis C virus

(HCV) NS3-NS4A protease. Consequently, the

compound of the present invention interferes with


13

the life cycle of the hepatitis C virus and is also

useful as an antiviral agent. The present invention

further relates to a pharmaceutical composition

comprising the aforementioned compound for

administration to a subject suffering from HCV

infection.


14

NEW APPLICATIONS FOR THE INDUSTRIAL DESIGNS

Design

No. Title & Class Applicant

19/11/2019

20172 TANK (Class-03) Hamza Mehmood, Trading as Plastic

World (Pvt) Limited

20173 Divider (Class-03) Sayyed Engineers Limited

20174 Compass (Class-03) Sayyed Engineers Limited

20/11/2019

20175 (ROUND JAR) (Class-03) Mr. OZAIR UR REHMAN S/o NAIM UR

REHMAN KHAN

20176 Bottle (Class-03) Muhammad Ali as M.A.A International,

20177 PERFUME BOTTLE (Class-04) Anoop Kumar










20187 MANHOLE COVER (Class-03) Anoop Kumar

21/11/2019

20188 Pouch for Drinking Water (Class-05) Ali Asghar, M&H Product


15

22/11/2019

20189 Sharpener (Class-3)

Muhammad Ali Sultan S/O Sultan Salahuddin 2) Sohail Mumtaz S/O

Mumtazuddin 3) Suleman Saleem S/O Saleemuddin

20190 Eraser (Class-03)

Muhammad Ali Sultan S/O Sultan Salahuddin 2) Sohail Mumtaz S/O

Mumtazuddin 3) Suleman Saleem S/O Saleemuddin

20191 BOX (Class-03) Nawaz Ahmed S/o Irshad Muhammad,



16

REGISTRATION OF DESIGNS

The following designs have been registered.

S. No. Design

No. Title & Class Applicant

21-11-2019

1. 19721 Foldable (Class-12) Hafiz Muhammad Saleem Iqbal

2. 19849 RUBBER TRANSMISSION BELT

(Class 3) SHAHRYAR

3. 19973 PEN (Class-03) Ameer Ullah Khan

4. 20002 MP3 AUDIO PLAYER (Class 1) MUHAMMAD SARWAR

5. 20129 Carpet (Class-08) Ch. Mubasher Hussain (Chief

Executive), Nayyer Industries (Pvt.) Ltd.,



7. 20016 Pencil Box (Class-03) INDUS PENCIL INDUSTRIES (PVT)

LIMITED









-sd-

(Dr. Muhammad Fayyaz Ahmad)

Controller of Patents

& Registrar of Designs

Ph: 99230591

weekending:- 22-11-2019 legal publication date:- …ipo.gov.pk/system/files/191227.pdfmr. iftikhar...

Documents